Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| agilon health, inc.AGL · Entity 4698 | Director | April 14, 2022 | April 20, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
agilon health, inc.
Report date April 14, 2022 · Filed April 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,892 |
Reported balance
After 2022-04-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-04-14 · Grant · Acquired 6,936 · Balance 18,892 F1: Restricted stock units that vest in full on April 14, 2023, subject to continued service as a director. F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units that vest in full on April 14, 2023, subject to continued service as a director.
F2: Includes restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2022 Filed Apr 20, 2022 20:55 UTC | agilon health, inc. AGL · Entity 4698 | GrantCommon Stock | 6,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-025011 · doc4.xml · nonDerivative · entry 1 Gourdine Michelle A · CIK 0001855956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,892 F1 · shares: Restricted stock units that vest in full on April 14, 2023, subject to continued service as a director. F2 · balance_after: Includes restricted stock units. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:03 UTC | agilon health, inc. AGL · Entity 4698 | PurchaseCommon Stock | 5,000 | $23.00 | $115,000.00 |
DisclosureSEC source: 0001209191-21-027759 · doc4.xml · nonDerivative · entry 1 Gourdine Michelle A · CIK 0001855956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,956 F1 · balance_after: Includes restricted stock units. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 21:25 UTC | agilon health, inc. AGL · Entity 4698 | GrantOptions (Rights to Buy) · Derivative | 11,843 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027015 · doc4.xml · derivative · entry 2 Gourdine Michelle A · CIK 0001855956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,843 Underlying: Common Stock · 11,843 shares Expires 2031-04-14 F2 · derivative.exercise_date: Options that vest in three equal installments on each anniversary of April 14, 2021, subject to continued service as a director. F2 · derivative.expiration_date: Options that vest in three equal installments on each anniversary of April 14, 2021, subject to continued service as a director. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 21:25 UTC | agilon health, inc. AGL · Entity 4698 | GrantCommon Stock | 6,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027015 · doc4.xml · nonDerivative · entry 1 Gourdine Michelle A · CIK 0001855956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,956 F1 · shares: Restricted stock units that vests in full on April 14, 2022, subject to continued service as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.